ADA Assay Workflow for Drug-Interference-Free Antibody Detection

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for detecting anti-drug antibodies (ADAs) are hindered by drug interference, leading to false negatives and under-reporting of ADA incidence and titers, especially in the presence of long-lived monoclonal antibody therapies, due to the formation of immune complexes that interfere with detection and quantitation.

Innovation Solution

A novel ADA assay method involving polyethylene glycol (PEG) precipitation followed by acid or basic dissociation of drug/ADA complexes, immobilizing dissociated ADAs on a high-capacity substrate to prevent reformation, allowing specific detection using labeled drug.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Measurement precision

If conventional ADA detection methods are used, then detection simplicity is maintained, but drug interference causes false negatives and under-reporting of ADA incidence

Engineering Contradiction:

ImproveADA detection accuracyVSAvoidassay method complexity

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The assay is divided into distinct sequential steps: (1) PEG precipitation to separate drug-ADA complexes from free drug, (2) acid dissociation to break complexes and release ADA, (3) immobilization of dissociated ADA on substrate, and (4) detection using labeled drug. This segmentation allows each step to address specific interference issues without compromising overall accuracy.

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

PEG precipitation is performed as a preliminary step before detection to pre-separate drug-ADA complexes from free drug in the sample. This preliminary action removes the interfering free drug before the actual ADA detection occurs, ensuring accurate measurement without requiring complex real-time interference management.

Inventive Principle:

Principle #10Preliminary action

2Measurement precision

If drug and ADA are not separated during immobilization, then assay procedure is simplified, but drug interference prevents accurate ADA detection

Engineering Contradiction:

ImproveADA quantitation accuracyVSAvoidassay procedure simplicity

Core Design Contradiction:

Measurement precisionVSEase of operation

Solution Approach 1:

The assay exploits parameter changes in pH to control the binding state of ADA. Acidic pH conditions are used to dissociate drug-ADA complexes and prevent their reformation during immobilization, while subsequent neutralization restores physiological conditions for specific detection. This parameter change ensures drug and ADA remain separated during critical immobilization steps.

Inventive Principle:

Principle #35Parameter changes

Solution Approach 2:

PEG acts as an intermediary substance that facilitates the separation of drug-ADA complexes from free drug through precipitation. This intermediary enables the subsequent acid dissociation step to work effectively by concentrating the complexes in a separable form, simplifying the overall separation process while maintaining detection accuracy.

Inventive Principle:

Principle #24Intermediary (Mediator)

3Measurement precision

If wash-out periods are used to allow drug clearance, then false negatives are reduced, but early time point ADA assessment is missed and productivity decreases

Engineering Contradiction:

ImproveADA detection reliabilityVSAvoidassay throughput and timing

Core Design Contradiction:

Measurement precisionVSProductivity

Solution Approach 1:

The assay converts the harmful effect of drug presence into a beneficial feature by using the drug-ADA complexes themselves as the target for detection. Instead of requiring drug clearance, the method detects ADA bound to drug in complexes, turning the interference problem into a detection advantage. This allows immediate assessment without wash-out periods.

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

PEG precipitation is performed as a preliminary separation step that concentrates drug-ADA complexes and removes free drug interference before detection. This preliminary action enables accurate ADA quantitation at early time points when drug concentrations are high, eliminating the need for delayed assessment after drug clearance.

Inventive Principle:

Principle #10Preliminary action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The method effectively reduces drug interference, enabling accurate and reproducible detection of ADAs, even in the presence of high drug concentrations, by ensuring drug and ADA remain separated during immobilization, thus improving assay sensitivity and accuracy.

Implementation Method 1

contacting the drug/ADA complexes with polyethylene glycol (PEG), to form a precipitate comprising drug/ADA complexes

Methodology Applied

Scientific EffectPrecipitation: Precipitation

Implementation Method 2

contacting the precipitate with a solution to dissociating the drug/ADA complexes

Methodology Applied

Scientific EffectAcid dissociation:

Implementation Method 3

contacting the precipitate with a solution to dissociating the drug/ADA complexes

Methodology Applied

Scientific EffectBase dissociation:

Implementation Method 4

determining the presence of or amount of said ADA by contacting the immobilized ADA with drug labeled with a detectable label

Methodology Applied

Scientific EffectAntigen-antibody binding:

Data Source

PatentUS12566186B2Assays for detecting the presence or amount of an anti-drug antibody

Publication Date: 2026.03.03 GENZYME CORP

AI summary

Methods and kits for detecting antibodies (e.g., anti-drug antibodies). Such methods and kits permit the detection of, for example, anti-drug antibodies in human body fluids, such as blood, plasma and serum.